PIII

Business Context and Reporting Period

P3 Health Partners Inc. (P3) is a patient-centered, physician-led population health management company operating primarily in the Medicare Advantage (MA) market. The company utilizes an at-risk shared savings model, receiving capitated payments from health plans in exchange for managing the total healthcare costs of attributed members. This Form 10-Q covers the quarterly period ended June 30, 2025.

As of June 30, 2025, P3 served approximately 114,100 at-risk members through a network of roughly 2,800 primary care physicians across 24 markets in four states. The company is classified as a smaller reporting company and a non-accelerated filer.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total operating revenue decreased by 6% ($23.4 million) for the three months ended June 30, 2025, compared to the same period in 2024. This was primarily driven by an 11% reduction in at-risk membership (from 128,100 to 114,100) due to the strategic termination of underperforming payor contracts and affiliate providers.
• Medical Expense Reduction: Medical expenses decreased by 4% ($13.8 million) quarter-over-year, aligning with the reduction in member count.
• Premium Deficiency Reserve: The company recorded a benefit of $6.0 million for the quarter (up 76% from $3.4 million in 2024) and $12.9 million for the six-month period (up 439% from $2.4 million). This reflects management's assessment that increased medical expenses will lead to future losses on certain contracts.
• Operating Loss: Operating loss widened to $34.1 million for the quarter from $31.3 million in the prior year period, despite lower expenses, due to the significant revenue contraction.
• Debt Financing: The company secured significant new debt financing in 2025, including the VGS 4 Promissory Note ($30 million) and VGS 5 Promissory Note (up to $70 million), carrying high interest rates (19.5%) with significant paid-in-kind (PIK) components.

Outlook, Risks, and Management Commentary

• Going Concern Warning: Management has concluded that there is substantial doubt about the company's ability to continue as a going concern within one year of the report date. The company has a working capital deficit of $348.5 million and relies on raising additional capital to fund operations and refinance indebtedness.
• Liquidity Strategy: P3 is actively exploring raising capital through debt and equity issuances. Failure to secure funding could force the company to curtail activities, discontinue operations, or sell assets.
• Strategic Shifts: The company is actively exiting underperforming contracts to improve long-term profitability, which has temporarily reduced revenue and membership counts.
• Key Risks:
  • Regulatory & Legal: The company is cooperating with a Civil Investigative Demand (CID) from the U.S. Department of Justice regarding arrangements with insurance agents and brokers.
  • Debt Covenants: There is a risk of default if the company cannot maintain compliance with debt covenants, particularly given the high interest rates and PIK structures of recent financing.
  • Nasdaq Listing: While the company regained compliance with Nasdaq bid price requirements via a 1-for-50 reverse stock split in April 2025, there is no assurance of sustained compliance.
  • California Solvency: Affiliated physician groups in California must maintain specific cash-to-claims ratios to avoid sanctions or termination of business.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $38.6 million in unrestricted cash against the $348.5 million working capital deficit and upcoming debt maturities.
• Debt Terms: Review the specific terms of the VGS 4 and VGS 5 promissory notes, particularly the 19.5% interest rates, PIK interest obligations, and back-end fees.
• DOJ Investigation: Monitor updates regarding the Civil Investigative Demand from the Department of Justice concerning broker remuneration.
• Membership Trends: Assess whether the strategic exit of underperforming contracts has stabilized the medical margin or if further revenue declines are anticipated.
• Capital Raising: Track the company's progress in securing the additional debt or equity financing required to address the going concern uncertainty.